No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
FDA Staff Cuts Are Already Impacting Regulatory Work, Biotech Leaders Warn
RBC Capital Initiates Apellis Pharmaceuticals(APLS.US) With Hold Rating, Announces Target Price $24
RBC Trims Price Target on Apellis Pharmaceuticals to $24 From $25, Keeps Sector Perform Rating
Apellis Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
Apellis Pharmaceuticals Analyst Ratings
Mizuho Securities Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $30